Candel Therapeutics, Inc. 8-K

What Happened

• On May 15, 2026, Candel Therapeutics, Inc. (CADL) filed a Form 8-K (Item 7.01) disclosing an investor presentation delivered via live webcast reviewing extended follow-up data from the phase 3 trial of aglatimagene besadenovec in localized prostate cancer. The same data were presented at the American Urological Association (AUA) 2026 Annual Meeting on May 15, 2026.

Key Details

• Presentation date: May 15, 2026 (investor webcast and AUA presentation).
• Drug/trial: aglatimagene besadenovec — extended follow-up data from the Phase 3 localized prostate cancer trial.
• Exhibits furnished with the 8-K: Exhibit 99.1 (Investor Presentation dated May 15, 2026) and Exhibit 99.2 (Press Release dated May 15, 2026).
• The presentation is posted on the company’s investor relations site (not incorporated by reference into the 8-K).

Why It Matters

• This filing publicly notifies investors that Candel has released updated, longer-term Phase 3 clinical data for its lead candidate, which is a key development milestone in the company’s clinical-stage pipeline. Investors can review the furnished presentation and press release for details on efficacy/safety and any metrics disclosed; such data can influence clinical outlook and investor assessment of the program’s progress.